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Abstract 
Polycystic ovarian syndrome (PCOS) is the most prevalent metabolic disorder in reproductive-age women, 
indeed multifactorial condition. Cytokines such as TNF-alpha and IL-6 have influence on several metabolic 
activities. The increase in dehydroepiandrosterone (DHEA) is thought to play an important role in IL-6-mediated 
pathogenetic effects in PCOS women. The aim of this study is to explore whether TNF-alpha and IL-6 are 
correlated hormone levels in PCOS disease.  We recruited 65 PCOS patients and 45 healthy controls. The serum 
IL-6, TNF-alpha, levels were measured by ELISA and clinical characteristics were measured. Both serum IL-6, 
TNF-alpha levels (p<0.01), or the serum TSH, FSH, LH, PRL levels were significantly higher in the patients of 
PCOS (p<0.01). Serum IL-6 levels were correlated with DHEAS level (r=-0.4186, p<0.01). DHEAS level tended 
to be higher in PCOS women with a correlation between age, BMI, IL-6 level and positively correlated with 
FSH, LH and PRL levels (p<0.01). There was an elevation of TSH level in the PCOS group (2.4±1.5) vs. control 
group (1.8±1.6). However, in control samples, there was no correlation between TNF alpha and IL-6, while in 
the PCOS samples positive correlation, was obtained. Oral glucose tolerance test (OGTT) was higher than the 
control (20.38±13.2) group vs. PCOS women (128.33±33.8) but only 3.44 % of them had Type II diabetes. 
HOMA-IR index was higher in the PCOS group (8.26±15.06) vs. control group (2.12±0.88) too. There was a 
correlation between age and IL-6 level and BMI. Serum IL-6 and DHEAS levels were significantly altered in 
PCOS patients and determined which might be PCOS prognostic importance. 
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1. Introduction 
Polycystic ovary syndrome (PCOS) is an endocrine abnormality in women of reproductive age with the 
prevalence ranging from 9 to 18% (1). The disease is mainly is determined by the disfunction of ovulation, 
resistance of insulin, excess of androgens in circulation (2). The pathophysiology of the disease is still unknown 
but there is high evidence that chronic inflammation and oxidative stress may have a significant role in the 
pathophysiology of PCOS (3,4). Cytokines soluble proteins which are small molecules are produced in response 
to antigens. They are initially defined as mediators for regulating the adaptive immune systems (5). Cytokines 
serve as chemical messengers such as tumor necrosis factors (TNF), interleukins (IL), interferons, chemokines, 
and growth factors (6). They mediate in intracellular signaling pathways which are characterized by pro-
inflammatory and anti-inflammatory effects (7). TNF-α is a well-considered pro-inflammatory cytokine and IL-6, 
is considered to have both pro-and anti-inflammatory actions (8). Beyond IL-6 is known for its immunological 
importance, IL-6 pointed as a molecule that acts at various physiological and pathological levels in different 
systems and processes as well energy balances and metabolism (9). It is known that TNF-α, IL-6 has an 
important role in an inflammatory response which may induce phospholipases, sphingomyelinases, and 
concomitantly proteolyze phosphatidylcholine and sphingomyelin synthesizing enzymes as well as effects on the 
phospholipid metabolism (10). Cytokine production from various tissues generally induced by free oxygen 
radicals which are mediators of signal transduction pathways (11). It is reported that they have a potential role to 
inhibit the activation of oxidant-mediated transcription factors as well as preventing the transcriptional activation 
of inflammatory cytokines (12). Imbalance in metabolic status is commonly associated with changes in 
metabolic rate related to oxygen consumption which may lead to enhancement of the generation of oxidative 
stress status (13). Chronic inflammation is characterized by an increase in proinflammatory cytokines and 
chemokines which is associated with insulin resistance (14). There are researches have revealed that serum 
oxidative markers are significantly increased in patients with PCOS compared with the normal (15). Therefore, 
supplementation with compounds containing anti-inflammatory and antioxidant properties may be effective in 
improving the pathological condition of PCOS (16).  In the light of the foregoing consideration, we aimed to 
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compare circulating hormone levels by cytokines to contribute the relation between hormone concentrations and 
inflammation in PCOS women.  
  
2. Methods  
2.1. Subjects 
A total of 110 subjects recruited 65 diagnosed with PCOS and 45 healthy females served as control subjects 
aimed to match BMI and age among groups. PCOS diagnostic evaluation and biological materials of the PCOS 
diagnosed patients were performed and provided by two expert physicians working in the field. Healthy control 
groups were selected according to inclusion criteria who had not to have both a history of infertility, 
hysterectomy or ovariectomy, or menstrual problems and hyperandrogenism signs.  The participants were 
recruited from the attending Department of Obstetrics and Gynecology in Health Science University at Kanuni 
Sultan Suleyman Training and Research Hospital in İstanbul with the approval of the Ethics Committee and 
permission (date 2021.03 and number 85) depending on the guide of Helsinki Declaration. The data collected 
from patients who were involved in this experiment were subject to the Personal Data Act and Act on Ethical 
Review for research involving human subjects. All research participants gave their permission to be part of 
a study. BMI was calculated as kg/m2. The details of participants are depicted in Table1.   
 
2.2. Laboratory methods 
2.2.1. TNF-α ELISA  
TNF-α ELISA kit (Elabscience C., Cat no: E-EL-R0019, China) was used for the quantitative measurements 
Thermo Scientific Microplate Reader (USA) was used for the measurements at 450 nm with the kit detection 
was 78.13-5000 pg/mL.  
2.2.2. IL-6 ELISA  
Quantitative measurements of IL-6 in serum samples were carried out by using IL-6 ELISA kit (Elabscience, E-
EL-H0102, USA).  Optical density was measured at 450 nm via Thermo Scientific Microplate Reader (USA) 
and with kit detection range was 7.81-500 pg/mL.  
 
3. Statistical analysis  
Data were analyzed using Statistical Package for Social Science version 17 (SPSS Inc., Chicago, IL) and were 
expressed as mean ± SD. The concentration of parameters was compared between the groups using repeated 
measures of The Analysis of Variance (ANOVA) test followed with Bonferroni. Correlation analyses were 




A total of 110 individuals were enrolled in our study. The average age of patients with PCOS 29.5±5.1 was years, 
with the height 162±6 and weight 62.3±9.7, control subjects were 26±5.2 years 1.61±6.18 height and 73.1±19.5 
weight was for control subjects. Comparison of the study groups concerning study variables is summarized in 
Table 1. The body mass index (kg/m2) was 38.4±5.8 for the control group and 30.1±12.8 with a mean (SD) for 
the PCOS group. To evaluate and quantify hirsutism in women the Ferriman–Gallwey (FG) score was calculated, 
it was 6.7±5.1 for the control group and 13.9±7 for the PCOS group. Furthermore, 49 of (84.48 %) 58 women 
had ovulatory dysfunction with irregular ovulation condition but not completely absent (oligo) as well 9 of 
(14.51 %) PCOS diagnosed women were not having irregular ovulation condition. Additionally, 51 (87.93%) of 
PCOS women had menstrual irregularity and 7 of (12.06%) PCOS women were not having menstrual 
irregularity. Likewise, infertility was absent in 32 (54.23%) PCOS women, but 11 had (18.64%) infertility, 10 
women (16.94%) state were unknown, 4 women were (6.77%) unmarried and 1 was (1.69%) virgin. Withal, 34 
(58.62 %) of PCOS women had PCOS in the family but not have 24 (41.37 %) of them PCOS in the family. 38 
(65.51%) of our participants were treated with drugs and 20 of them (34.48%) were not used any drug. Also, 30 
(51.72%) of the PCOS group had a history of cardiac disease in their family but 28 (48.27%) of them had not. 
Finally, 13 (22.43%) of PCOS women had additional diseases and 45 (77.58%) of them had not any additional 
disease.  
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Table 1. Baseline characteristics of study participants for PCOS n=65 and n=45 for the control group.  
Baseline characteristics of study participants 
 Control PCOS 
N 45 65 
Age 29.5±5.12 26±5.25 
Height(cm) 162±6.03 1.61±6.18 
Weight (kg) 62.3±9.78 73.1±19.5 
Body Mass Index (kg/m2) 30.1±12.8 38.4±5.87 
Oligo/Anovulation    
Present Null 84.48 % 
Absent  Null 14.51 % 
Menstrual irregularity   
Present    Null  87.93% 
Absent     Null  12.06% 
Infertility   
Absent   35(83.33%)  54.23% 
Present    Null 18.64% 
Unknown   7 (16.66 %) 16.94% 
Unmarried    Null  6.77% 
Virgin    Null 1.69% 
Ferriman–Gallwey (FG) score   6.7±5.1 13.9±7 
Hyperandrogenemia   
Present Null 81,03% 
Absent  Null 18,96% 
PCOS in the family   
 Absent  Null  41.37 % 
Present Null 58.62 % 
Treatment (Drugs)    
Absent Null  65.51% 
Present  Null  34.48% 
History of cardiac disease in the family   
Absent  Null  48.27% 
Present  Null 51.72% 
Additional disease    
Absent  Null 77.58% 
Present Null 22.43% 
In Fig.1 we compared the hormone concentration of PCOS women and control subjects. Women with 
PCOS had high levels of Luteinizing hormone (LH) (IU/L) secretions (10.5±6.3) which was significantly 
(p<0.01) higher than the control group (5.3±2.5). High levels of LH contribute to the high levels 
of androgens (male hormones such as testosterone), and this along with low levels of follicle-stimulating 
hormone (FSH) (IU/L) secretion (5.5±1.7) compared to the control group (6.8±3.6) that contributes to poor egg 
development and an inability to ovulate. The lack of ovulation alters levels of estrogen, FSH, and LH.  Estradiol 
(nmol/L) level (44.9±46) was lower than the control group (72.6±10) with the significant p-value (p<0.001), 
while androgen levels Dehydroepiandrosterone sulfate (DHEAS) (nmol/L) (276±89.8) was higher than usual 
compared to the control group (191±50.5). Prolactin (PRL) level was elevated in PCOS subjects (16.8±8.56) too 
compared to the control group (14.1±10.6) as seen in Table 2.  Extra male hormones disrupt the menstrual cycle, 
so women with PCOS get fewer periods than usual. Most women with PCOS are surprised to find that 
their estrogen levels fall within the normal range (about 25-75 pg/ml). This may be because the high levels of 
insulin and testosterone found in women with PCOS are sometimes converted to estrogen. High levels 
of estrogen are known as estrogen dominance and can occur in women with PCOS disease. PCOS is a hormone 
imbalance that can cause irregular periods, unwanted hair growth, and acne. Also, we measured Thyroid-
stimulating hormone (TSH) levels both in the control and PCOS group, there was an elevation of TSH level in 
the PCOS group (2.4±1.5) compared to the control group (1.8±1.6).  
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Table 2. The mean and SD of hormonal parameters in PCOS and healthy control women (n=65, n=45).  
Hormonal parameters Control PCOS 
Dehydroepiandrosterone sulfate (DHEAS) (nmol/L) 191±50.5 276±89.8 
Follicle-stimulating hormone (FSH) (IU/L 6.86±3.6 5.53±1.72 
Luteinizing hormone (LH) (IU/L) 5.35±2.5 10.5±6.38 
Estradiol (nmol/L) 72.6±10 44.9±46 
Thyroid-stimulating hormone (TSH) 1.85±1.63 2.44±1.54 
PRL 14.1±10.6 16.8±8.56 
LH/FSH 2.1±2.19 0.90±0.45 
Finally, related to PCOS disease in young women, our results show that the lack of ovulation alters levels of 
estrogen, progesterone, FSH, and LH. Estrogen and progesterone levels are lower than usual, while androgen 
levels are higher than usual as in previous studies. Estrogens are a group of steroid hormones that are lipids made 
up of four fused rings of carbon. Also, Progesterone (P4) and Testosterone (T) are steroid form hormones. 
Follicle-stimulating hormone (FSH) and Luteinizing hormone (LH) is a glycoprotein structured hormone. 
Prolactin (PRL) Human prolactin is a non-glycosylated protein, which contains a simple polypeptide chain of 
198 amino acids. Comparatively, LH/FSH levels were higher than the Control group but lower than 2.5 in PCOS 
women.  
As shown in Table 3, Oral Glucose Tolerance Test (OGTT) (128.3±33) was lower than 140 mg/dl on the 
other hand two women (3.44%) had Type II diabetes. HOMA IR was elevated in PCOS women (8.2±15) 
compared to the control group (2.1±0.8). 
Metabolic parameters Control PCOS 
Oral Glucose Tolerance Test (OGTT)  120.38±13.2 128.33±33.8  
Diabetes metabolic parameters Null Type II, 2 (3.44%) 
HOMA IR 2.12±0.88 8.26±15.06 
Table 3. Shows mean and SD of metabolic parameters in patients with, PCOS and controls.   
Additionally, 65.51% of the patients with PCOS were not used specific drug treatments. Totally 18 (31.03%) 
PCOS patients were used specific drugs for the treatment of metabolic disease. As indicated in Table 4, the 
participants were using different drugs such as yasmin, oxytocin, and additionally 13 patients had different 
diseases. 
Drugs for the treatment of PCOS                   Additional Diseases 
Yasmin                          5 (8.62%) Hypothyroidy                                    3 (5.17 %) 
Oxytocin                        3 (5.17%) Guatr                                                 2 (3.44%) 
Diane                             2 (3.44 %) Hypercholesterolemia                       2 (3.44%) 
Qlairista                         2 (3.44 %) Asthma                                              2(3.44%) 
Lazer                              2 (3.44 %) Type2 Diabetes                                 2(3.44%) 
Andropor                       1 (1.72 %) Psoriasis                                            1(1.72%) 
Glifor                             1 (1.72 %) Hydronephrosis                                 1(1.72%)  
Duphastone                   1 (1.72 %) 
Inofolic                         1  (1.72 %) 
Table 4. Drug treatments and additional diseases of PCOS patients. n=58.  
 
Figure 1. Hormone concentrations(pg/l). Black color represents control group (n=45); red color represents 
PCOS group (n=65). Tested with analysis of variance ANOVA followed with post-hoc analysis. A significant 
difference was expressed as a p-value which was calculated by one-way ANOVA test followed by Bonferroni’s 
post hoc test. p was considered significant at < 0.05. Significance levels: *p < 0.05, ***p < 0.001 vs. control 
group. 
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As illustrated in PCOS patient’s TNF-alpha levels were higher (226.3±43) than control (80.02±26.48) with 
a significant p-value (p< 0.001). IL-6 level in PCOS women compared to the controls too. There was an 
elevation in PCOS women (346.9 ±15.71) compared to the control group (180.6 ± 55.51). Together, these 
alterations cytokine and oxidative stress status imbalance contribute to inhibition on TNF-α or IL-6 acting to 
modify the metabolism under PCOS condition (Figure 2). 
 
Figure 2. Cytokine level TNF-alpha (pg/ml) and IL-6 (pg/ml) and oxidative stress status measured in the blood 
serums. Groups are presented in legends. Data are presenting mean (±SD) values. The total number of subjects 
in each group: n control =45, n PCOS = 65. Significance levels: ***p < 0.01 control vs. PCOS group. 
The only statistically significant results from the Pearson correlation test obtained from Cytokine levels and 
laboratory test conditions were presented in Figure 2. As is shown, a positive and negative correlation was 
obtained. A positive correlation means, that if we observed an increase of the first factor, the second one also 
increases, while negative correlations mean, that if we observed an increase of the first factor, the second one 
decreases. When we compared results obtained for control and PCOS samples, differences in the kind and values 
of correlation, was visible. In the control samples negative correlation between IL-6 and DHEAS levels in 
control patients was obtained, while in PCOS samples, this correlation was not noticed. However, in control 
samples, there was no correlation between TNF alpha and IL-6, while in the PCOS samples positive correlation, 
was obtained. 
 
5. Discussion  
In this study, we highlighted the significant role of IL-6 and TNF- alpha as important inflammatory cytokines 
and androgenic hormone DHEAS, as markers with PCOS disease. As it is known LH/FSH >2.5 is considered as 
PCOS disease, but our results showed that women with PCOS may have LH/FSH level <2.5. but this ratio was 
higher than control women as in previous studies (16).Our correlation analysis signified important points. As a 
pro-inflammatory marker, we measured IL-6 level and inflammatory marker TNF-alpha both in PCOS and 
healthy women, the results showed that IL-6 and TNF-alpha correlate in PCOS women but not in healthy women 
as previous studies reported both parameters may have a role in PCOS related disease (17). IL-6 level has a 
significant difference between PCOS and control women. Also, when we take a cut-off between 20-25 and 23-30 
age women, IL-6 had a rise with advancing age both in PCOS and healthy women. Previous studies had shown 
that IL- 6 may rise with advancing age (18), our results showed that IL-6 tends to be a rise in PCOS women too.   
It is known that IL-6 is a cytokine that is being produced either by immune cells or nonimmune cells some 
typically endocrine which have pathophysiologic roles in humans. Ref. Recent studies have shown that IL-6 and 
TNF-alpha are the product of adipose tissue claimed that they may have an important role in lipid metabolism 
(19,20). IL-6 is a cytokine that is regulated by hormones. The metabolic product of IL-6 and hormones has a 
correlation and IL-6 has many endocrine effects for instance it has a role in the stimulation of the hypothalamic-
pituitary-adrenal axis during inflammatory stress and has influence intermediary metabolism (21,22). Ersler et al, 
showed that IL-6 with the age-associated increase is largely prevented by life span-prolonging dietary control 
(18). This result suggests dietary control may have related to IL-6 level and maybe a therapeutic approach for 
PCOS women. Contrary to previous findings our clinical reports and experiments obtained from PCOS women 
support and extend the major role that IL-6 plays in metabolism and endocrine. As an additional contribution, we 
find that IL-6 may correlate with DHEAS hyperandrogenic hormone as previous studies (23). Furthermore, LH 
and DHEAS hormone levels were significantly correlated with IL-6 levels. Interestingly DHEAS and IL- 6 have 
a correlation in healthy women but not in PCOS women (24). Additionally, ANOVA and following Bonferroni 
multiple comparisons showed that DHEAS level had significant changes between groups and among subjects in 
PCOS women and control women. DHEAS level tended to be higher in PCOS women. Also, there was a 
correlation between age, BMI, IL-6 level, and DHEAS level as recent studies (25). As a result, our results 
suggest that endocrine hormone concentrations were significantly higher in PCOS. Finally, PCOS is generally 
considered as a metabolic disorder, researchers may focus on IL-6 as an inflammatory marker and DHEAS as a 
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hyperandrogenic hormone and maybe the relation between these markers since that may have an important role 
in the management of the disease and thus may improve women’s health. the hormone may have an impact on 
the metabolic disorder.  
 
6. Conclusion  
In conclusion, PCOS is a gender-specific complicated endocrine disorder relating to defects in psychological, 
metabolic, and reproductive functions. Clinical reports are important traces for the consideration of the disease. 
IL-6 and DHEAS levels showed alterations among and between PCOS and healthy participants depending on 
age and BMI. There is a low-grade inflammation in PCOS women. 
Therefore, as a result, IL-6 and TNF- alpha rises against low-grade inflammation in the PCOS can be found 
and there is a correlation with DHEAS with IL-6 level. Furthermore, well-planned prospective research is 
required to explore more about androgens and cytokines.   
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